Compare QBTS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QBTS | MDGL |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | 388 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.1B |
| IPO Year | N/A | 2005 |
| Metric | QBTS | MDGL |
|---|---|---|
| Price | $24.27 | $503.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $32.53 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 39.7M | 245.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $81.05 | $58.39 |
| Revenue Next Year | $93.13 | $48.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.75 | $279.33 |
| 52 Week High | $46.75 | $615.00 |
| Indicator | QBTS | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 52.28 |
| Support Level | $23.20 | $498.59 |
| Resistance Level | $24.78 | $502.97 |
| Average True Range (ATR) | 2.40 | 19.92 |
| MACD | -0.54 | 2.65 |
| Stochastic Oscillator | 20.00 | 86.62 |
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.